Dimethyl fumarate for treating relapsing multiple sclerosis

Dimethyl fumarate (BG-12) first line oral treatment for people with multiple sclerosis: STUDY

TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients

Biogen (NASDAQ: BIIB) today announced new data that continue to support TECFIDERA® (dimethyl fumarate) as an effective, long-term treatment for people who are living with relapsing forms of multiple sclerosis (MS). Data show TECFIDERA significantly reduced relapses and disability progression in newly-diagnosed relapsing-remitting MS (RRMS) patients who had highly active disease. Additional data indicate TECFIDERA showed strong and sustained efficacy over five years in RRMS patients who were previously treated with an interferon (interferon beta-1a/b [IFN]) or glatiramer acetate (GA). These results will be presented at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.

FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments

This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY

Could This Study Help Lead to a Cure for Select Multiple Sclerosis Patients?

For a disease that affects 2.5 million people around the globe and more than 400,000 people in the United States, it's a shame that so little is known about multiple sclerosis despite the amount of money being put into research of the disease.

Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate: STUDY

Alkermes' multiple sclerosis prodrug looks good in Phase I, has Biogen Idec's Tecfidera in its sights

Dr. Elliot Ehrich

Alkermes ($ALKS) said the safety profile of its clinical-stage multiple sclerosis drug compares favorably to that of Biogen Idec's Tecfidera, citing the candidate's Phase I trial results on 104 patients.

Forward Pharma: One of Baupost’s new positions

Baupost adds new stake in Forward Pharma
Seth Klarman’s The Baupost Group added a 11.72% stake in Forward Pharma (FWP). A 13G filing  in November indicated that the fund owns 5,367,300 shares in Forward Pharma.

Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple Sclerosis

–– Novel, Oral Product Candidate Provided Monomethyl Fumarate Exposures Comparable to TECFIDERA®, With Favorable Gastrointestinal Tolerability ––

This Could Be Game-Changing News in the Battle Against Multiple Sclerosis

For a disease that affects more than 400,000 people in the United States and approximately 2.5 million around the globe, multiple sclerosis is arguably not getting its fair share of attention from drug developers and researchers. According to the National Institutes of Health, which has an annual budget near $40 billion, only $115 million is expected to be spent on MS research in 2015.

Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview: STUDY

Multiple Sclerosis, Don’t Let It Define You

One way to understanding any disease is to talk to your doctor and another is to read about the disease from various medical sources. It is not always wise to rely on one source for information. With how much information we come across these days on the internet, it shows how much people are talking about a particular, disease, war, or anything else of great interest. One disease that is of interest is Multiple Sclerosis or MS.

Biogen Idec MS drug is approved by European regulators

European regulators Wednesday gave Cambridge biotech Biogen Idec Inc. approval to sell a new kind of injectable drug to treat multiple sclerosis.

Biogen MS blockbuster Tecfidera earns high marks for safety - FiercePharma

TEVA'S COPAXONE PATENT IS UP AND ITS DESPERATE TO KEEP PATIENTS & INSURERS

Teva is trying to persuade patients and their doctors to switch from the daily injection to a new, three-times-a-week version! PLUS: trying to get insurers to pay for it!